None listed
Conditions
Brief summary
There are currently no objective ways to diagnose migraine and there is no way to determine what underpins the origins of migraine in each individual. This leaves doctors and migraine sufferers without the key information that would allow for optimal treatment selection and specific diagnosis. What is needed is a simple test that can diagnose migraine patients from people without migraine and can guide treatment selection. This study will therefore explore whether some new technologies may be useful as a blood test(s) to diagnose migraine.
Interventions
Participants will complete an online questionnaire (up to approximately 20 minutes duration) about their general health and history of headaches/migraines to determine their eligibility for the study, and the experimental group to which they belong (either healthy control, episodic migraine, or chronic migraine). This may require an additional interview with the researchers (up to approximately 30 minutes duration). A single blood sample will then be obtained from each participant (up to an appr
Participants will complete an online questionnaire (up to approximately 20 minutes duration) about their general health and history of headaches/migraines to determine their eligibility for the study, and the experimental group to which they belong (either healthy control, episodic migraine, or chronic migraine). This may require an additional interview with the researchers (up to approximately 30 minutes duration). A single blood sample will then be obtained from each participant (up to an approximately 15 minute appointment), and the blood-based biomarkers under investigation compared between experimental groups.
Sponsors
The University of Adelaide
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
Healthy Participants: 1. No history of migraine. 2. Otherwise in good general health (including only non-problematic headaches (if any)). Migraine participants: Diagnostic criteria will be from The International Classification of Headache Disorders, 3rd Edition; The International Headache Society, Cephalagia, 2018: 38, 1-211. 1. Episodic migraine, with or without aura, where individuals experience an average of at least 2 episodes of migraine per month in the last 3 months. 2. Chronic migraine, where individuals experience an average of at least 15 days of headache per month of which at least 8 days of migraine per month for the last 3 months. Chronic migraine participants are eligible with or without concomitant medication overuse. 3. Otherwise in good general health.
Exclusion criteria
1. Presence of an inflammatory process, or clinically significant infection in the last 4 weeks. 2. Immunisation within the last 4 weeks. 3. Clinically significant renal, hepatic, cardiac, autoimmune disease. 4. Current use of immunosuppressant medication, such as systemic corticosteroid, hydroxychloroquine, methotrexate or azathioprine. 5. Inability to read or comprehend the written information provided. 6. Current use of medications known to affect TLR responsiveness, including amitriptyline. 7. Current pregnancy.
Outcome results
None listed